Your browser doesn't support javascript.
loading
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss, Andreas; Park-Simon, Tjoung-Won; Albanell, Joan; Lassen, Ulrik; Cortés, Javier; Dieras, Veronique; May, Marcus; Schindler, Christoph; Marmé, Frederik; Cejalvo, Juan Miguel; Martinez-Garcia, Maria; Gonzalez, Iria; Lopez-Martin, Jose; Welt, Anja; Levy, Christelle; Joly, Florence; Michielin, Francesca; Jacob, Wolfgang; Adessi, Céline; Moisan, Annie; Meneses-Lorente, Georgina; Racek, Tomas; James, Ian; Ceppi, Maurizio; Hasmann, Max; Weisser, Martin; Cervantes, Andrés.
Affiliation
  • Schneeweiss A; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Park-Simon TW; Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany.
  • Albanell J; Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain.
  • Lassen U; Rigshospitalet, Copenhagen, Denmark.
  • Cortés J; Ramon y Cajal University Hospital, Madrid, Spain.
  • Dieras V; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • May M; Department of Medical Oncology, Institute Curie, Paris, France.
  • Schindler C; Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany.
  • Marmé F; Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany.
  • Cejalvo JM; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Martinez-Garcia M; Department of Medical Oncology, Biomedical Health Research Institute INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain.
  • Gonzalez I; Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain.
  • Lopez-Martin J; Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain.
  • Welt A; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Levy C; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
  • Joly F; Departments of Clinical Research Unit and Medical Oncology, Centre François Baclesse, Caen, France.
  • Michielin F; Departments of Clinical Research Unit and Medical Oncology, Centre François Baclesse, Caen, France.
  • Jacob W; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Adessi C; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany. wolfgang.jacob@roche.com.
  • Moisan A; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Meneses-Lorente G; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Racek T; Pharma Research and Early Development (pRED), Roche Innovation Center Welwyn, Welwyn Garden City, UK.
  • James I; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Ceppi M; A4P Consulting Ltd, Sandwich, UK.
  • Hasmann M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Weisser M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Cervantes A; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Invest New Drugs ; 36(5): 848-859, 2018 10.
Article in En | MEDLINE | ID: mdl-29349598
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2018 Type: Article